BTIG Reiterates Buy Rating on vTv Therapeutics (VTVT): 'VTVT checks every box'

April 13, 2026 12:29 PM

BTIG analyst Kambiz Yazdi reiterated a Buy rating and $49.00 price target on vTv Therapeutics (NASDAQ: VTVT)The analyst commented, "vTv ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found